Exelixis’ Cabozantinib Targets Particularly Sick Thyroid Cancer Patients

Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug’s profile.

Strong efficacy in a particularly sick patient population could help differentiate Exelixis Inc.’s Phase III medullary thyroid cancer candidate cabozantinib from the only FDA-approved drug for this rare disease – AstraZeneca PLC’s Caprelsa, the company suggested during an Oct. 27 earnings call.

Medullary thyroid cancer is a small market, with an estimated 1,300 to 2,200 new cases in the U.S. each year....

More from Clinical Trials

More from R&D